AGI reports $45 million Q3 revenue, secures FDA acceptance for AG-101

AGI (AGBK) posted third‑quarter 2026 results on Tuesday, reporting $45 million in revenue and a net loss of $119 million, while confirming its cash runway through the end of 2027. The company’s CEO, Dr. Laura Chen, highlighted the FDA’s acceptance of the company’s Biologics License Application for its lead gene‑therapy candidate, AG‑101, and announced a partnership with a major European pharma to co‑develop a second‑in‑class treatment for Duchenne muscular dystrophy.

The earnings beat comes after a turbulent year in which AGI’s stock fell 35 percent amid concerns over delayed trial data and a broader biotech sell‑off triggered by rising interest rates. The company has been betting on its platform that combines CRISPR editing with viral vectors, a strategy that many investors thought was too early for commercial returns. Recent positive data from the Phase 2b trial of AG‑101, showing a 30 percent improvement in functional scores, helped restore confidence and prompted the FDA’s faster review timeline.

Analysts noted that the $45 million revenue figure, driven largely by a $30 million upfront payment from the European partner and $10 million in milestone receipts, exceeded consensus estimates of $38 million. The partnership also brings a $25 million milestone payment and a $50 million co‑development fund, bolstering the balance sheet. Shares jumped 12 percent in after‑hours trading, and several brokerage houses upgraded the stock to “hold” from “sell,” citing the reduced regulatory risk and clearer path to market for AG‑101.

Looking ahead, AGI plans to file for marketing approval of AG‑101 in the United States by the first quarter of 2027, with a launch expected later that year if approved. The company will also initiate a Phase 1 study of its next‑generation therapy, AG‑202, targeting a different rare disease cohort. Success in these milestones could solidify AGI’s position in the rapidly expanding gene‑therapy market, which analysts project to exceed $30 billion by 2030. The next earnings call, slated for early February, will likely focus on regulatory updates and the financial impact of the new partnership.